EA202191176A1 - Поливалентные модуляторы регуляторных т-клеток - Google Patents

Поливалентные модуляторы регуляторных т-клеток

Info

Publication number
EA202191176A1
EA202191176A1 EA202191176A EA202191176A EA202191176A1 EA 202191176 A1 EA202191176 A1 EA 202191176A1 EA 202191176 A EA202191176 A EA 202191176A EA 202191176 A EA202191176 A EA 202191176A EA 202191176 A1 EA202191176 A1 EA 202191176A1
Authority
EA
Eurasian Patent Office
Prior art keywords
binding domain
polivalent
modulators
regulatory
cell
Prior art date
Application number
EA202191176A
Other languages
English (en)
Inventor
Чонмин КИМ
Ниранджана НАГАРАДЖАН
Джеффри Грив
Original Assignee
Делиниа, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Делиниа, Инк. filed Critical Делиниа, Инк.
Publication of EA202191176A1 publication Critical patent/EA202191176A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Настоящее изобретение относится к соединениям, которые содержат IL-2 рецептор-связывающий домен и ST2-связывающий домен, например, антитело или его фрагмент, которые специфически связываются с ST2. Способы, описанные здесь, обеспечивают способ лечения состояния введением индивиду, нуждающемуся в этом, терапевтически эффективного количества соединения, содержащего IL-2 рецептор-связывающий домен и ST2-связывающий домен.
EA202191176A 2018-10-31 2019-10-30 Поливалентные модуляторы регуляторных т-клеток EA202191176A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862753397P 2018-10-31 2018-10-31
PCT/US2019/058854 WO2020092554A1 (en) 2018-10-31 2019-10-30 Multivalent regulatory t cell modulators

Publications (1)

Publication Number Publication Date
EA202191176A1 true EA202191176A1 (ru) 2021-07-28

Family

ID=70464133

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191176A EA202191176A1 (ru) 2018-10-31 2019-10-30 Поливалентные модуляторы регуляторных т-клеток

Country Status (13)

Country Link
US (1) US20210403579A1 (ru)
EP (1) EP3873923A4 (ru)
JP (1) JP2022513406A (ru)
KR (1) KR20210084587A (ru)
CN (1) CN113286814A (ru)
AU (1) AU2019369498A1 (ru)
BR (1) BR112021008355A2 (ru)
CA (1) CA3117529A1 (ru)
EA (1) EA202191176A1 (ru)
IL (1) IL282502A (ru)
MX (1) MX2021005008A (ru)
SG (1) SG11202104120VA (ru)
WO (1) WO2020092554A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
JP2018528763A (ja) 2015-07-31 2018-10-04 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムの除去のためのペプチドおよび抗体
ES2941966T3 (es) 2017-09-28 2023-05-29 Immpact Bio Ltd Una plataforma universal para preparar un receptor de antígeno quimérico inhibidor (ICAR)
US20210054088A1 (en) * 2018-03-23 2021-02-25 Eli Lilly And Company Anti-cd137 antibodies for combination with anti-pd-l1 antibodies
MX2022007754A (es) * 2019-12-20 2022-07-19 Regeneron Pharma Nuevos agonistas de il2 y metodos de uso de estos.
WO2021211416A1 (en) * 2020-04-13 2021-10-21 Maddon Advisors Llc Ace2- and tmprss2-targeted compositions and methods for treating covid-19
CA3181077A1 (en) * 2020-06-29 2022-01-06 Douglas W.P. HAY Humanized anti-emap ii therapeutic antibodies
CA3183196A1 (en) * 2020-07-07 2022-01-13 Steven D. Goodman Combination therapies for the treatment and prevention of biofilms
AU2021336547A1 (en) * 2020-09-04 2023-04-06 ImmPACT Bio USA Inc. Bicistronic inhibitory chimeric antigen receptor (iCAR)/activating chimeric antigen receptor (aCAR) constructs for use in cancer therapies
WO2022216915A1 (en) * 2021-04-08 2022-10-13 Sana Biotechnology, Inc. Cd8-specific antibody constructs and compositions thereof
TW202304965A (zh) 2021-05-04 2023-02-01 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法
CN115989244A (zh) * 2021-08-06 2023-04-18 上海驯鹿生物技术有限公司 Cd5和cd7双靶点的全人源嵌合抗原受体(car)及其应用
WO2023097275A1 (en) * 2021-11-23 2023-06-01 Invetx, Inc. Anti-ngf antibodies and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399847B1 (en) * 1996-11-25 2008-07-15 The General Hospital Corporation Nucleic acids encoding artificial P-selectin ligands
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
SI2556090T1 (sl) * 2010-04-09 2016-07-29 Critical Care Diagnostics, Inc. Protitelesa in testi topnega človeškega ST-2
WO2012009544A2 (en) * 2010-07-14 2012-01-19 Amgen Inc. Domain insertion immunoglobulin
MX360336B (es) * 2010-07-16 2018-10-30 Adimab Llc Star Colecciones de anticuerpos.
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
AR091069A1 (es) * 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
US9631191B2 (en) * 2012-12-04 2017-04-25 Alexey Gennadievich Zdanovsky System for production of antibodies and their derivatives
SG10201913158PA (en) * 2015-04-03 2020-02-27 Eureka Therapeutics Inc Constructs targeting afp peptide/mhc complexes and uses thereof
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
BR112019011799B1 (pt) * 2016-12-13 2021-12-21 Delinia, Inc Proteína de fusão, proteína dimérica e composição farmacêutica

Also Published As

Publication number Publication date
KR20210084587A (ko) 2021-07-07
SG11202104120VA (en) 2021-05-28
EP3873923A1 (en) 2021-09-08
EP3873923A4 (en) 2023-02-08
BR112021008355A2 (pt) 2021-08-03
JP2022513406A (ja) 2022-02-07
WO2020092554A1 (en) 2020-05-07
IL282502A (en) 2021-06-30
MX2021005008A (es) 2021-06-15
AU2019369498A1 (en) 2021-05-20
CA3117529A1 (en) 2020-05-07
US20210403579A1 (en) 2021-12-30
CN113286814A (zh) 2021-08-20

Similar Documents

Publication Publication Date Title
EA202191176A1 (ru) Поливалентные модуляторы регуляторных т-клеток
MD3394103T2 (ro) Combinație de anticorpi anti-PD-1 și anticorpi bispecifici anti-CD20/anti-CD3 pentru tratamentul cancerului
EA201891495A1 (ru) Биспецифические анти-cd20/анти-cd3 антитела для лечения острого лимфобластного лейкоза
EA202092847A1 (ru) Антитела к cd3 и их применение
EA202191580A1 (ru) Биспецифичные антитела анти-cd28 x анти-cd22 и их применение
BR112017025080A2 (pt) composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
EA201891028A1 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv
JO3701B1 (ar) مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
EA201992526A1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
MX2021000399A (es) Moleculas de anticuerpo que se unen a cd137 y ox40.
EA202092420A1 (ru) Антитело против pd-l1 и его применение
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
MX2021000397A (es) Moleculas de union a mesotelina y cd137.
MX2020002406A (es) Anticuerpo anti-epha4.
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
EA201990895A1 (ru) Антитела к о1 и варианты их применения
AU2017269839A1 (en) Methods for treatment of refractory generalized myasthenia gravis
MX2021000387A (es) Fragmentos de union a fc que comprenden un sitio de union al antigeno cd137.
EA201990222A1 (ru) Антитела к o2 и пути их применения
EA201990988A1 (ru) Антитела против chikv и пути их применения
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA202191231A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ЭНДОКРИННОЙ ОФТАЛЬМОПАТИИ С ПРИМЕНЕНИЕМ АНТИ-FcRn АНТИТЕЛ
MX2022008471A (es) Anticuerpo anti-angptl3 y uso del mismo.